A way out of the antibiotics crisis
Interdisciplinary research team is developing new strategies against resistant pathogens in the Carl Zeiss Foundation's “CZS Breakthroughs” programme
| Ute Schönfelder, FSU Jena
Every year, more people die as a result of an infection with antibiotic-resistant germs. According to a recent study, this number could rise to more than 39 million worldwide by 2050. There is no easing of the global antibiotics crisis in sight. What is particularly alarming is that the problem is largely homemade.
“The fact that resistance genes to antibiotics are spreading so strongly and quickly is due to their excessive and, above all, untargeted use," says Prof. Dr Kai Papenfort from the University of Jena. This is because broad-spectrum antibiotics generally not only eliminate the pathogens causing the disease, but often damage the patient's entire microbiome. "In this way, both pathogens and the patient's own microflora develop resistance and more and more antibiotics lose their effectiveness,” continues the microbiologist.
Five million euros in funding from the Carl Zeiss Foundation
Together with Prof. Dr Miriam Rosenbaum, Professor of Synthetic Biotechnology at the University of Jena and head of the Bio Pilot Plant at the Leibniz-HKI, Papenfort is leading a research project that aims to counter the antibiotics crisis with a completely new conceptual approach. The "SynThera" project (Synthetic therapeutic microbes for tailored antimicrobial therapies) will be supported by the Carl Zeiss Foundation with around 5 million euros over the next five years. In its thematic focus "Life Science Technologies", the foundation promotes research at the interface of engineering and life sciences.
Specifically effective and locally limited
The team, which includes Rosenbaum and Papenfort as well as eight other research groups from the University of Jena and the HKI, relies on the support of other non-pathogenic microbes to combat pathogens. “We want to design microorganisms in such a way that they recognise pathogens and render them harmless in a highly specific and locally limited way,” explains Miriam Rosenbaum. On the one hand, this means that significantly fewer side effects can be expected than with the use of existing antibiotics. It also minimizes the risk of resistance developing. Such an approach also opens up the possibility of personalized medicine.
With this approach, the Jena researchers not only want to develop therapeutics against acute infections, such as EHEC bacteria or clostridia. The customized drugs are also to be used as prophylaxis, for example in chemotherapy and organ transplant patients – wherever antibiotics are currently part of standard treatment.
About the Carl Zeiss Foundation
The Carl Zeiss Foundation’s mission is to create an open environment for scientific breakthroughs. As a partner of excellence in science, it supports basic research as well as applied sciences in the STEM subject areas (science, technology, engineering and mathematics). Founded in 1889 by the physicist and mathematician Ernst Abbe, the Carl Zeiss Foundation is one of the oldest and biggest private science funding institutions in Germany. It is the sole owner of Carl Zeiss AG and SCHOTT AG. Its projects are financed from the dividend distributions of the two foundation companies.
Contact
Kai Papenfort, Univ.-Prof. Dr
Professorship for General Microbiology
- kai.papenfort@uni-jena.de
- +49 3641 9-49311
- +49 3641 9-49312
Bioinstrumentezentrum, Room M1-E3
Winzerlaer Straße 2
07745 Jena
Miriam Agler-Rosenbaum, Univ.-Prof. Dr
Professorship for Synthetic Biotechnology
- miriam.rosenbaum@leibniz-hki.de
- +49 3641 +49 3641 532-1120
- +49 3641 +49 3641 532-2120
Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie – Hans-Knöll-Institut (Leibniz-HKI)
Beutenbergstraße 11a
07745 Jena
Involved units
Accreditation
Do you wish to obtain our latest press releases regularly?
Please enter your email address and click the Subscribe button. You will then receive our press releases by email. You have the option to cancel the subscription at any time.